We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Developments Related to SARS

By HospiMedica staff writers
Posted on 27 Jan 2004
The U.S. More...
Centers for Disease Control and Prevention (Atlanta, GA, USA) has announced that the importation of palm civets into the United States is banned until further notice. Civets are regarded as potential carriers of the severe acute respiratory syndrome (SARS) virus.

Growing indirect evidence suggested that exposure to certain wild animals might be associated with SARS infection, although there has been no evidence that humans have become infected with the virus from direct contact with certain wild animals. However, the epidemiology of the initial outbreak suggests that there may have been multiple introductions from animals to humans. To date, a SARS-like coronavirus has been isolated from many palm civets, and the government of Guangdong province in China has ordered that civet cats be eradicated. The U.S. order does not include restrictions on the domestic movement of civets already in the country.

A second development relating to SARS is the announced finding by the Chinese University of Hong Kong that two genetic markers can help predict the outcome of SARS in patients. Those with a genetic marker known as HLA-DRB1-0301 show more resistance against SARS, while those with HLA-B-0703 have a much greater risk of becoming infected with SARS. The results were based on an analysis of blood samples of 90 SARS patients, aged 22-85, compared to the blood samples from almost 19,000 bone marrow donors in Hong Kong. The researchers say the markers could help doctors identify high-risk people and treat them more aggressively. They caution, however, that their findings are preliminary.





Related Links:
CDC
Chinese U. of Hong Kong

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.